# Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression

> **NCT01716104** · PHASE3 · COMPLETED · sponsor: **Materia Medica Holding** · enrollment: 260 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Afalaza
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01716104
- **Lead sponsor:** Materia Medica Holding
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11
- **Primary completion:** 2016-11
- **Final completion:** 2016-11
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2018-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01716104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01716104, "Clinical Trial of Safety and Efficacy of Afalaza in Patients With Symptoms of Benign Prostatic Hyperplasia and Risk of Progression". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01716104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*